Royalty Pharma’s index additions and fund support draw fresh attention

Royalty Pharma (RPRX) has been added to the Russell 1000 Defensive and Russell 1000 Value Defensive indices, while Meridian Hedged Equity Fund recently highlighted the stock and kept its position through the quarter.

Recent index additions and fund interest have coincided with strong price momentum, with Royalty Pharma’s share price delivering a 19.01% 90 day return and a 46.91% year to date share price return, while its 3 year total shareholder return sits at 101.24%.

If this kind of interest in biopharma focused businesses has your attention, it could be a good moment to see what else is moving via the 41 healthcare AI stocks.

With Royalty Pharma trading near its analyst price target and showing a large intrinsic value gap on some models, investors now face a key question: is there still meaningful upside left, or is the market already pricing in future growth?

Most Popular Narrative: 3.6% Undervalued

Compared with Royalty Pharma’s last close at $57.09, the most followed narrative fair value of $59.25 points to a modest upside and sets up a detailed case built on future cash flow strength.

The robust scientific pipeline, driven by advancements in biologics, gene therapies, and next-generation medicines like daraxonrasib, creates high-value assets that can enter into blockbuster status. Participation in these early, high-impact assets (as in the Revolution Medicines deal) positions Royalty Pharma for long-duration, high-growth royalty streams, directly benefitting long-term revenue and earnings.

Want to see what is sitting behind that fair value for Royalty Pharma? The narrative leans heavily on faster earnings, higher margins, and a reset future multiple. Curious how those ingredients combine into $59.25 as today’s number? The full story connects those projections line by line.

Result: Fair Value of $59.25 (UNDERVALUED)

However, the bullish Royalty Pharma narrative still hinges on resolving the Alyftrek royalty dispute and managing concentration in key royalty streams, such as Trikafta and Spinraza.

Next Steps

With both risks and rewards in play for Royalty Pharma, it may be helpful to review the details for yourself. To see how investors are weighing both sides of the story, take a closer look at the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Royalty Pharma?

Do not stop with Royalty Pharma. The market is full of other opportunities, and a few minutes exploring fresh ideas now could make a real difference later.

• Spot potential value opportunities early by scanning 42 high quality undervalued stocks with strong fundamentals that might fit your return and risk expectations.
• Strengthen the quality of your watchlist by focusing on companies in the solid balance sheet and fundamentals stocks screener (48 results) that aim for financial resilience.
• Hunt for off-the-radar opportunities with the screener containing 19 high quality undiscovered gems before they attract broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.